Trial Profile
Phase II Multicenter, Dose Ranging Study on the Safety and Antiemetic Efficacy of One Day Intraveous Dosing of GW597599 Administered With Ondansetron HCL in a Female Subjects Undergoing Surgical Procedures of High Emetogenic Risk
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Vestipitant (Primary) ; Vestipitant (Primary) ; Ondansetron
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- Sponsors GSK
- 02 Sep 2009 Additional location identified as reported by ClinicalTrials.gov.
- 01 Mar 2008 New trial record.